This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gottlieb, A B Search for Related Content PubMed PubMed Citation Articles by Gottlieb, A B Social Bookmarking                         What's this?

Clinical research helps elucidate the role of tumor necrosis factor-in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes

WH Conzen Chair in Clinical Pharmacology, Professor of Medicine, Director, Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School>, gottliab{at}umdnj.edu

Psoriasis is a life-disabling disorder in which 8-10% of patients aged 18-54 actively contemplate suicide because of their disease. Owing to the toxicity and=or inconvenience of current, FDA-approved treatments far moderate-to-severe psoriasis, they are generally used intermittently so that patients experience cycles of remission-flare-remission-flare, etc. The challenge to drug development for moderate-to-severe psoriasis is to provide safe and effective long-term management. Immunobiologics offer the hope for safe, long-term control of psoriasis because they lack targeted organ toxicity. Thus the treatment paradigm may shift from one of intermittent treatment limited by toxicity with resultant flares of disease, to one similar to that seen in diabetesor hypertension in which disease is controlled continuously.Additionally, immunobiologics may alter the natural history of psoriasis. Etanercept, which targets TNF-, controls signs and symptoms and halts joint destruction in patients with psoriatic arthritis. The long-lived remissions observed after cessation of alefacept or infliximab (anti-TNF-monoclonal antibody) treatment lead this author to speculate that these immunobiologics may actually alter the natural history of the cutaneous manifestations of psoriasis.

Key Words: psoriasis • TNF- • immunobiologics • T cell activation • cytokines

Lupus, Vol. 12, No. 3, 190-194 (2003)
DOI: 10.1191/0961203303lu354xx


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Kochetkova, T. Trunkle, G. Callis, and D. W. Pascual Vaccination without Autoantigen Protects against Collagen II-Induced Arthritis via Immune Deviation and Regulatory T Cells J. Immunol., August 15, 2008; 181(4): 2741 - 2752. [Abstract] [Full Text] [PDF]

				P. Pallotta, G. Cianchini, M. Ruffelli, and P. Puddu Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis Rheumatology, January 1, 2006; 45(1): 116 - 117. [Full Text] [PDF]